21 results about "Immunoglobulin A" patented technology

Provided is an immunological measurement method for measuring a target substance in a sample, wherein an antigen-antibody reaction is performed at least once in the presence of an enzyme that specifically decomposes immunoglobulin A, abbreviated as IgA.

The present invention provides an immunologic stimulant which contains Lactobacillus helveticus, and wherein the Lactobacillus helveticus has three functions: the activation of dendritic cell-like cells, the induction of the production of immunoglobulin A (IgA), and the induction of the production of interleukin-12 (IL-12).

The inventions relates to Immunoglobulin A (IgA) or a pharmaceutical composition comprising IgA for use in the treatment of an infectious disease of or in an immune privileged organ, such as the eye, fetus, placenta, central nervous system (CNS) and / or testicles caused by a bacterial, fungal, viral or parasitic infection, in particular caused by bacteria of the human microbiome. IgA-coated pathogens can be addressed by FCAR+ and / or CD11c+ innate immune cells, for example by phagocytosis, or by activation of the complement system. The use of IgA or a pharmaceutical composition comprising IgA in immune privileged sites is advantageous because in contrast to IgG, IgA-coated pathogens do not trigger activation of C1q, a protein used for the controlled pruning of synapses. This prevents neuronal damage in said immune privileged organ(s), while at the same time allowing an antibody-mediated immune response in said organs.

The present application provides an immunostimulant containing Lactobacillus helveticus, wherein the Lactobacillus helveticus has three functions: activation of dendritic cell-like cells, induction of immunoglobulin A (IgA) production, and induction of interleukin-12 (IL-12) production.

An immunological assay method for measuring a target substance in a sample, wherein at least one antigen-antibody reaction is performed in the presence of an enzyme that specifically decomposes immunoglobulin A (IgA).

The present disclosure refers to Immunoglobulin A (IgA) for use in a method for treating or preventing dry eyes in a patient wherein said Immunoglobulin A (IgA) is obtained from plasma, blood plasma or plasma fractions, and wherein said Immunoglobulin A (IgA) is administered to said patient in an effective dosage. In particular, the disclosure pertains to the use in a treatment or prevention of dry eye disease and the respective complications like infections. Further, the disclosure refers to IgA obtained from plasma, blood plasma or plasma fractions and a pharmaceutical composition comprising such IgA.